Episode 49. Updates on Low-Risk MDS with Dr. Maximilian Stahl

from Blood Cancer Talks · host Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. Here are the trials we discussed: 1. IWG 2019 response criteriahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/ 2. MEDALIST trial: Luspatercepthttps://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 3. COMMANDS trial : Luspatercept https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00874-7/abstracthttps://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00203-5/abstract 4. IMerge trial: Imetelstat https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01724-5/abstract

Episode metadata supplied by the publisher feed · Published Aug 14, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Episode 49. Updates on Low-Risk MDS with Dr. Maximilian Stahl

0:00 43:23

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Blood Cancer Talks?

This episode is 43 minutes long.

When was this Blood Cancer Talks episode published?

This episode was published on August 14, 2024.

Can I download this Blood Cancer Talks episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!